¼¼°èÀÇ ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ½ÃÀå
Preclinical Respiration and Inhalation Lab Equipment
»óǰÄÚµå : 1795318
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 170 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2,600¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2,030¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2,600¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠȣÈí Àåºñ´Â CAGR 4.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 1,820¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈíÀÔ Àåºñ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 530¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ½ÃÀåÀº 2024³â¿¡ 530¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 420¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.0%¿Í 3.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È£Èí±â ¹× ÈíÀÔ ½Ã½ºÅÛ Å×½ºÆ®ÀÇ Á¤È®µµ¿Í 󸮷®À» ³ôÀÌ´Â ±â¼úÀº ¹«¾ùÀΰ¡?

ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ´Â ÃøÁ¤ Á¤È®µµ, ³ëÃâ Á¦¾î, »ý¹°ÇÐÀû ¸ðµ¨¸µ Çâ»óÀ» À§ÇØ ºü¸£°Ô ±â¼ú °³¼±ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Àü»êÈ­´ÜÃþÃÔ¿µ ½Ã½ºÅÛ, Àü½Å ³ëÃâ è¹ö, ÄÚ Àü¿ë ³ëÃâž, ¿¡¾î·ÎÁ¹ ¹ß»ýÀåÄ¡ÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº º¸´Ù Á¤È®Çϰí Àϰü¼º ÀÖ´Â ÀÎü ÈíÀÔ ½Ã³ª¸®¿À¸¦ ½Ã¹Ä·¹À̼ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ÇöÀç °íÇØ»óµµ ¾Ð·Â ¼¾¼­, Â÷µ¿ À¯·®°è ¹× ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁý ¼ÒÇÁÆ®¿þ¾î¸¦ ÅëÇÕÇÏ¿© ÀǽÄÀÌ ÀÖ´Â ¼³Ä¡·ù ¹× ¸¶ÃëµÈ ÇÇÇèÀÚÀÇ Á¶¼ö·®, È£Èí¼ö, ºÐ´ç ȯ±â·® ¹× ÃÖ´ë È£±â À¯·®À» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¡¾î·ÎÁ¹ Àü´Þ ½Ã½ºÅÛÀº ½º¸¶Æ® ÆÄƼŬ »çÀÌÀú, °íÁÖÆÄ ÃÊÀ½ÆÄ ºÐ¹«±â, ¸Å½º Ç÷οì ÄÁÆ®·Ñ·¯¸¦ ÅëÇØ ÁøÈ­Çϰí ÀÖÀ¸¸ç, È£Èí±âÀÇ ´Ù¾çÇÑ ¿µ¿ª¿¡ °ÉÃÄ ¹Ýº¹ °¡´ÉÇÑ ÀÔÀÚ Ä§ÂøÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. »õ·Î¿î ½Ã½ºÅÛÀº ¶ÇÇÑ »ý¸®ÀûÀ¸·Î ÀûÀýÇÑ ¿¡¾î·ÎÁ¹ Á¶ÀýÀ» À§ÇØ °¡½À ¹× ¿Âµµ Á¶ÀýÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿ »ùÇøµ ¹× ¿ø°Ý ÃøÁ¤ Áö¿ø ½Ã½ºÅÛÀº È£Èí±â ¹ÙÀÌ¿À¸¶Ä¿ ¼öÁý, °¡½º ±³È¯ ÃøÁ¤, ¾à¹° Èĺ¸ ¹× ȯ°æ µ¶¼º ¹°Áú¿¡ ¹ÝÀÀÇϴ ȣÈí ¾ïÁ¦ ¹× Æó Àڱؼº ¸ð´ÏÅ͸µ¿¡ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÀüÀÓ»ó ¾àµ¿ÇÐ, µ¶¼ºÇÐ, ÈíÀÔ Ä¡·áÁ¦ °³¹ß ÆÄÀÌÇÁ¶óÀο¡¼­ ±Þ¼º ¹× ¸¸¼º ³ëÃâ ÇÁ·ÎÅäÄÝÀ» ¸ðµÎ Áö¿øÇÕ´Ï´Ù.

ÀüÀÓ»ó È£Èí±âÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ´Â ¿¬±¸ ºÐ¾ß´Â?

ÀüÀÓ»ó È£Èí ÀåÄ¡´Â Æó ¾à¹°Àü´Þ ¿¬±¸¿¡¼­ ¿À·§µ¿¾È »ç¿ëµÇ¾î ¿ÔÀ¸¸ç, ±× ¿ëµµ´Â ¿©·¯ ´ÙÇÐÁ¦Àû ¿µ¿ª¿¡¼­ È®´ëµÇ°í ÀÖ½À´Ï´Ù. È£Èí±â³»°ú ¿¬±¸°³¹ß¿¡¼­´Â õ½Ä, COPD, ³¶Æ÷¼º¼¶À¯Áõ, Ư¹ß¼º Æó¼¶À¯Áõ¿¡ ´ëÇÑ ÈíÀÔ¿ë ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ±â°üÁöÈ®ÀåÁ¦, ½Å±Ô »ý¹°ÇÐÀû Á¦Á¦ÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â µ¥ ÀÖ¾î ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÌ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¾¾çÇп¡¼­´Â ±â°ü³» ¹× ºñ°­³» Åõ¿© ÀåÄ¡·Î Áö¿øµÇ´Â È­Çпä¹ý ¾à¹°Àü´ÞÀ» À§ÇÑ ÈíÀÔ Á¦Á¦°¡ ÆóÁ¾¾ç¿¡¼­ ºÎÀ§º° Ä§Âø¿¡ ´ëÇØ ½ÃÇèµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ Àåºñ´Â ´ë±â¿À¿°¹°Áú, ³ª³ëÀÔÀÚ, »ê¾÷È­ÇÐÁ¦Ç°¿¡ ÀÇÇÑ ÈíÀÔµ¶¼ºÀ» Æò°¡Çϱâ À§ÇÑ È¯°æÀ§»ý ¿¬±¸¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. OECD, ¹Ì±¹ ȯ°æº¸È£Ã»(EPA) µî ±ÔÁ¦±â°üÀº È­ÇÐÁ¦Ç°ÀÇ À§Ç輺 Æò°¡ °¡À̵å¶óÀο¡¼­ ÈíÀÔ³ëÃâ½ÃÇèÀ» Á¡Á¡ ´õ Áß¿ä½ÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¨¿°º´ ¿¬±¸ÀÚµéÀº SARS-CoV-2, ÀÎÇ÷翣ÀÚ, °áÇÙÀ» Æ÷ÇÔÇÑ °ø±â Áß ¹ÙÀÌ·¯½º ¹× ¹ÚÅ׸®¾ÆÀÇ °¨¿°°ú È£Èí±â ¿µÇâÀ» Æò°¡Çϱâ À§ÇØ ÄÚ Àü¿ë ³ëÃâ½Ç°ú ¿¡¾î·ÎÁ¹È­ º´¿øÃ¼ ½Ã½ºÅÛÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ È£Èí ¿ø°Ý ÃøÁ¤°ú »ý¹°¾ÈÀü¼öÁØ(BSL) ȯ°æ¿¡¼­ÀÇ µ¿¹° ¸ðµ¨ ÅëÇÕÀº °¨¿° ¸ðµ¨¿¡¼­ ¸é¿ª ¹ÝÀÀ, Æó º´¸®, ¿ë·® ¹ÝÀÀ ¼Óµµ·Ð¿¡ ´ëÇÑ µ¥ÀÌÅÍÀÇ ÇØ»óµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

±ÔÁ¦ ¹× À±¸® ±âÁØÀº ¾î¶»°Ô ±â¼ú Çõ½Å°ú ÄÄÇöóÀ̾𽺸¦ ÃËÁøÇϰí Àִ°¡?

¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ÁøÈ­ÇÏ´Â µ¿¹° º¹Áö ±âÁØÀº ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½Ã½ºÅÛÀÇ ¼³°è ¹× °³¹ß¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. FDA, EMA, OECD µîÀÇ ±â°üÀº ÀÔÀÚ Å©±â ºÐÆ÷, Àü´Þ·®, Ä§Âø ÇÁ·ÎÆÄÀÏ µî ÈíÀÔ ¾à¹°Àü´Þ ÆÄ¶ó¹ÌÅÍ¿¡ ´ëÇÑ »ó¼¼ÇÑ Æ¯¼º Æò°¡¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ÀüÀÓ»ó½ÃÇè Àåºñ Á¦Á¶¾÷üµéÀº ÃßÀû °¡´ÉÇÑ ±³Á¤, ÀÚµ¿ Åõ¿© °ËÁõ, GLP Áؼö ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀ» °®Ãá °ËÁõ Áö¿ø ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿¡¾î·ÎÁ¹ ³ëÃ⠽ýºÅÛÀº ÇöÀç Àå±â°£ÀÇ ½ÇÇè ±â°£ µ¿¾È ÀϰüµÈ ¿ë·®À» Á¦°øÇϱâ À§ÇØ ½Ç½Ã°£ Çǵå¹é Á¦¾î¸¦ Áö¿øÇϵµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù.

µ¿¹°º¹Áö ±ÔÁ¦ ¶ÇÇÑ Àåºñ °³¹ßÀڵ鿡°Ô µ¿¹° ½ºÆ®·¹½º °¨¼Ò¿Í ³ëÃâ ÇÁ·ÎÅäÄÝ °³¼±À» Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ³ëÁî ¿Â¸® ½Ã½ºÅÛÀº ÀÎü°øÇÐÀû ±¸¼ÓÀåÄ¡¿Í °ø±â È帧ÀÇ ±³¶õÀ» ÃÖ¼ÒÈ­ÇÏ¿© ºÒÆíÇÔÀ» ÁÙÀ̱â À§ÇØ Àç¼³°èµÇ¾ú½À´Ï´Ù. Àü½Å è¹ö´Â ÇöÀç Ä­¸·ÀÌ·Î ±¸ºÐµÈ ±â·ù ±¸¿ª°ú ȯ°æ °­È­ ±â´ÉÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3R ¿øÄ¢(Replacement, Reduction, Refinement)¿¡ µû¶ó ÇÊ¿äÇÑ µ¿¹°ÀÇ ¼ö¸¦ ÃÖ¼ÒÈ­Çϸ鼭 µ¥ÀÌÅÍ Ã³¸®·®À» Çâ»ó½Ã۱â À§ÇØ ´ÙÁß µ¿¹° ÅÚ·¹¸ÞÆ®¸® ½Ã½ºÅÛ°ú ´ÙÁßÈ­ ÇÁ·¹Æ¼¸ð±×·¡ÇÁ¸¦ ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ Áؼö¿Í À±¸®Àû ¼³°èÀÇ °áÇÕÀº Áß°³ ¿¬±¸ ¹× ÀüÀÓ»ó °ËÁõÀ» À§ÇØ Á¶Á¤µÈ Â÷¼¼´ë È£Èí ¹× ÈíÀÔ Ç÷§ÆûÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ½ÇÇè½Ç Àåºñ ½ÃÀåÀÇ ¼ºÀåÀº Ç¥Àû Æó Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÈíÀÔ µ¶¼ºÇп¡ ´ëÇÑ ±ÔÁ¦ Àǹ«È­, È£Èí±â ¿¬±¸ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼¼°è ÅõÀÚ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ë±â¿À¿°, Èí¿¬, ±âÈĺ¯È­·Î ÀÎÇÑ ¸¸¼º È£Èí±âÁúȯ°ú È£Èí±â °¨¿°ÁõÀÇ ±ÞÁõÀº Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷µéÀÌ ÈíÀÔÁ¦Á¦¸¦ ¿ì¼±¼øÀ§·Î »ï°í ÀÖÀ¸¸ç, ÀüÀÓ»ó Æò°¡ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. Äڷγª ÀÌÈÄ ÈíÀÔ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ¹× ¹é½Å¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚ´Â ÀÌ·¯ÇÑ Ãß¼¼¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

Á¤ºÎ ¹× Çмú ±â°üÀº ƯÈ÷ ºÏ¹Ì, À¯·´ ¹× µ¿¾Æ½Ã¾Æ¿¡¼­ ¿¡¾î·ÎÁ¹ µ¶¼ºÇÐ, ¹ÙÀÌ¿À ¿¡¾î·ÎÁ¹ ºÀ¼â ¹× È£Èí±âÁúȯ ¸ðµ¨¸µÀ» À§ÇÑ ½ÇÇè½Ç ¿ª·®À» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÈíÀÔÁ¦ °³¹ßÀÚ´Â CRO¿Í Çù·ÂÇÏ¿© Àü´Þ ½Ã½ºÅÛÀ» °ËÁõÇϰí ÷´Ü Àåºñ¸¦ »ç¿ëÇÏ¿© Åõ¿© Àü·«À» ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. Àåºñ Á¦Á¶¾÷üµéÀº ¶ÇÇÑ ¿¬±¸ÀÚµéÀÌ Àü»êÀ¯Ã¼¿ªÇÐ(CFD) ¹× »ý¸®Àû ¾àµ¿ÇÐ(PBPK) ¸ðµ¨À» »ç¿ëÇÏ¿© Àΰ£ ¾àµ¿ÇÐÀ» ½Ã¹Ä·¹À̼ÇÇÒ ¼ö ÀÖµµ·Ï ¼ÒÇÁÆ®¿þ¾î ¹× ºÐ¼® Ç÷§Æû°ú Çϵå¿þ¾î¸¦ ¹øµé·Î Á¦°øÇϰí ÀÖ½À´Ï´Ù.

SCIREQ, Buxco/DSI(Harvard Bioscience), CH Technologies, InExpose, Kent Scientific µî ÁÖ¿ä ±â¾÷µéÀº ÅëÇÕ ÈíÀÔ Ç÷§Æû, ¸ðµâÇü ³ëÃâ Ÿ¿ö, AI ±â¹Ý ºÐ¼® Á¦Ç°±ºÀ» Æ÷ÇÔÇÑ Á¦Ç° ¶óÀÎÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. Á¦Ç°±ºÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ ´Ù¾çÈ­, È£Èí±â °Ç°­ ¹®Á¦ÀÇ È®»êÀ¸·Î ÀÎÇØ ÀüÀÓ»ó È£Èí ¹× ÈíÀÔ ÀåÄ¡ ½ÃÀåÀº Á¦¾à, ȯ°æ ¹× Çмú ¿¬±¸ ºÎ¹® Àü¹Ý¿¡ °ÉÃÄ ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(È£Èí Àåºñ, ÈíÀÔ Àåºñ), ÃÖÁ¾»ç¿ëÀÚ(CRO ¹× Çмú±â°ü ÃÖÁ¾»ç¿ëÀÚ, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Preclinical Respiration and Inhalation Lab Equipment Market to Reach US$26.0 Million by 2030

The global market for Preclinical Respiration and Inhalation Lab Equipment estimated at US$20.3 Million in the year 2024, is expected to reach US$26.0 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Respiration Equipment, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$18.2 Million by the end of the analysis period. Growth in the Inhalation Equipment segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Million While China is Forecast to Grow at 4.2% CAGR

The Preclinical Respiration and Inhalation Lab Equipment market in the U.S. is estimated at US$5.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Preclinical Respiration and Inhalation Lab Equipment Market - Key Trends & Drivers Summarized

How Is Technology Enhancing Precision and Throughput in Respiratory and Inhalation Studies?

Preclinical respiration and inhalation lab equipment is undergoing rapid technological refinement to improve measurement accuracy, exposure control, and biological modeling. Advances in plethysmography systems, whole-body exposure chambers, nose-only exposure towers, and aerosol generators are enabling researchers to simulate human inhalation scenarios with higher precision and consistency. These systems now integrate high-resolution pressure sensors, differential flow meters, and real-time data acquisition software that can monitor tidal volume, breathing rate, minute ventilation, and peak expiratory flow in conscious rodents or anesthetized subjects.

Aerosol delivery systems are evolving with smart particle sizers, high-frequency ultrasonic nebulizers, and mass flow controllers that allow reproducible particle deposition across different regions of the respiratory tract. Novel systems also incorporate humidification and temperature regulation for physiologically relevant aerosol conditioning. Automated sampling and telemetry-enabled systems are being used to collect respiratory biomarkers, perform gas exchange measurements, and monitor respiratory depression or pulmonary irritation in response to drug candidates or environmental toxins. These technologies support both acute and chronic exposure protocols in preclinical pharmacokinetics, toxicology, and inhaled therapeutics development pipelines.

Which Research Domains Are Expanding the Use of Preclinical Respiratory Equipment?

While preclinical respiration equipment has long been used in pulmonary drug delivery studies, its applications are expanding across several interdisciplinary domains. In respiratory medicine R&D, these systems are central to evaluating efficacy and safety of inhaled corticosteroids, bronchodilators, and novel biologics for asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis. In oncology, inhaled formulations for chemotherapeutic delivery are being tested for site-specific deposition in lung tumors, supported by intratracheal and intranasal dosing rigs.

The equipment is also being used in environmental health studies to assess inhalation toxicity from air pollutants, nanoparticles, and industrial chemicals. Regulatory bodies such as OECD and U.S. EPA are increasingly emphasizing inhalation exposure studies in their guidelines for chemical risk assessment. Additionally, infectious disease researchers are employing nose-only exposure chambers and aerosolized pathogen systems to evaluate transmission and respiratory effects of airborne viruses and bacteria, including SARS-CoV-2, influenza, and tuberculosis. The integration of real-time respiratory telemetry with animal models in biosafety level (BSL) environments is enhancing the resolution of data on immune response, lung pathology, and dose-response kinetics in infectious models.

How Are Regulatory and Ethical Standards Driving Technological Innovation and Compliance?

Stringent regulatory frameworks and evolving animal welfare standards are influencing the design and deployment of preclinical respiratory and inhalation systems. Agencies such as the FDA, EMA, and OECD require detailed characterization of inhaled drug delivery parameters, including particle size distribution, delivered dose, and deposition profile. As a result, preclinical equipment manufacturers are investing in validation-ready systems with traceable calibration, automated dosing validation, and GLP-compliant software platforms. Aerosol exposure systems are now engineered to support real-time feedback control for consistent dose delivery over extended experimental periods.

Animal welfare regulations are also pushing equipment developers to reduce animal stress and refine exposure protocols. Nose-only systems are being redesigned with ergonomic restraints and minimal airflow turbulence to reduce discomfort. Whole-body chambers now include partitioned airflow zones and environmental enrichment features. Furthermore, the 3Rs principle (Replacement, Reduction, Refinement) is encouraging multi-animal telemetry systems and multiplexed plethysmographs to improve data throughput while minimizing the number of animals required. This convergence of regulatory compliance and ethical design is driving a new generation of respiratory and inhalation platforms tailored for translational research and preclinical validation.

What Is Accelerating Market Growth for Preclinical Respiration and Inhalation Lab Equipment?

The growth in the global preclinical respiration and inhalation lab equipment market is driven by rising demand for targeted pulmonary therapeutics, regulatory mandates for inhalation toxicology, and global investment in respiratory research infrastructure. The surge in chronic respiratory conditions and respiratory infections-compounded by air pollution, smoking, and climate change-is pushing pharmaceutical and biotech firms to prioritize inhaled drug formulations, driving demand for preclinical evaluation tools. Post-COVID R&D investments in inhaled antivirals and vaccines have further accelerated this trend.

Governments and academic institutions are expanding laboratory capacity for aerosol toxicology, bioaerosol containment, and respiratory disease modeling, especially in North America, Europe, and East Asia. Inhalation drug developers are collaborating with CROs to validate delivery systems and optimize dosing strategies using advanced equipment. Equipment manufacturers are also bundling hardware with software and analytics platforms that allow researchers to simulate human pharmacokinetics using computational fluid dynamics (CFD) and physiologically based pharmacokinetic (PBPK) models.

Key players such as SCIREQ, Buxco/DSI (Harvard Bioscience), CH Technologies, InExpose, and Kent Scientific are expanding their product lines to include integrated inhalation platforms, modular exposure towers, and AI-powered analytics suites. With rising regulatory scrutiny, drug pipeline diversification, and the growing prevalence of respiratory health challenges, the preclinical respiration and inhalation equipment market is set to witness steady growth across pharmaceutical, environmental, and academic research sectors.

SCOPE OF STUDY:

The report analyzes the Preclinical Respiration and Inhalation Lab Equipment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Respiration Equipment, Inhalation Equipment); End-Use (CROs & Academic Institutes End-Use, Pharma & Biotech Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â